Navigation Links
ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
Date:10/21/2008

- Completion Follows FDA's Grant of Seven Years of Cinryze(TM) Marketing

Exclusivity for Prophylaxis against Hereditary Angioedema -

EXTON, Pa., Oct. 21 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced it has completed its acquisition of Lev Pharmaceuticals (OTC Bulletin Board: LEVP) following the approval earlier today of the transaction by Lev stockholders. Lev stockholders will receive $2.25 in cash, 0.042146 shares of ViroPharma common stock and one non- transferable contingent value right which entitles the holder to receive up to two contingent payments of $0.50 each in cash, payable upon the achievement of certain regulatory and commercial milestones, for each share of Lev common stock that they own. The total number of ViroPharma shares to be issued as part of the merger consideration is 7,286,286.

With the acquisition of Lev Pharmaceuticals, ViroPharma takes a significant step in broadening its portfolio of treatments for significant unmet medical needs, by acquiring Cinryze C1 esterase inhibitor (human), which recently received marketing approval by the U.S. Food and Drug Administration for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).

Hereditary angioedema, or C1 esterase inhibitor (C1-INH) deficiency, is a dangerous and potentially deadly inflammatory disease affecting up to 10,000 patients in the United States, caused by a genetic deficiency in an essential protein called C1 esterase inhibitor. Clinical studies have shown that prophylactic use of Cinryze, which increases the levels of C1 esterase inhibitor in the bloodstream, can significantly reduce the severity, duration and frequency of HAE attac
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
2. ViroPharma Announces Discontinuation of HCV-796 Development
3. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
4. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. ViroPharma to Present at the Natixis Bleichroeder Conference
6. ViroPharma to Present at Three Upcoming Healthcare Conferences
7. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
9. Genta Incorporated Announces Third Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... Research and Markets( http://www.researchandmarkets.com/research/ljsxt8/asia_pacific ) has announced the ... Market - Growth, Trends And Forecasts (2014 - 2019)" ... Asia Pacific market for Portable X-Ray Devices is ... 2020 X-Ray is a form of electromagnetic radiation ... especially bones. The need of point of care diagnostics has ...
(Date:5/27/2015)... 2015 Doctors from the Sheikh Zayed ... National Health System are the first in ... osteoma, a benign but painful bone tumor that commonly ... magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) method. Two patients, ... Shah , have been treated successfully in a research ...
(Date:5/27/2015)... , May 25, 2015 Research ... of the "2015 Strategies in the Global ... This comprehensive seven-country report contains 650 ... current suppliers and potential market entrants identify and ... testing market during the next five years. ...
Breaking Medicine Technology:Asia Pacific Portable X Ray Devices Market 2015 - Trends And Forecasts to 2019 2Children's National first in US to destroy bone tumors with incisionless surgery 2Children's National first in US to destroy bone tumors with incisionless surgery 3Children's National first in US to destroy bone tumors with incisionless surgery 4Global Coagulation Testing Market Strategies 2015 2Global Coagulation Testing Market Strategies 2015 3
... Sept. 8 BHR Pharma, LLC ... 3, multi-center pivotal trial ( www.synapse-trial.com ) to evaluate ... a neuroprotective agent for treating severe traumatic brain injury (TBI) patients ... approximately 1,200 patients with severe (Glasgow Coma Scale scores of 4-8), ...
... , , University ... drive up high blood pressure, raise risk of heart attack , ... known that measures such as exercise, a healthy diet and not smoking ... Michigan Health System have determined the very air we breathe can be ...
Cached Medicine Technology:BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury 2Inhaling a Heart Attack: How Air Pollution Can Cause Heart Disease 2Inhaling a Heart Attack: How Air Pollution Can Cause Heart Disease 3
(Date:5/27/2015)... Calls Upon Individuals, Organizations and Communities to ... initiative – a “Summer of Service” – seeks the help ... to grow the number of individuals and organizations serving Veterans. ... Veterans by inviting the community to visit and explore opportunities ... from 1 – 3:00 p.m. in the auditorium. , “We ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Ticket Down is a ... The Chicago Blackhawks are currently in the middle of their ... 3-2 in the series. If the Blackhawks can win tonight ... being played on Saturday, May 30th at the Honda Center in ... the best record in the Western Conference as they won the ...
(Date:5/27/2015)... Khanna Vision Institute (KVI) announced the launch ... on keratoconus eye disease . Keratoconus is commonly known ... onset in the teenage years. It worsens over the next ... clear part of the eye is defective. It becomes thin ... results in poor vision which cannot even be corrected with ...
(Date:5/27/2015)... York (PRWEB) May 27, 2015 ... filed on behalf of individuals who allegedly suffered ... to the use of the antipsychotic drug continue ... currently underway in Pennsylvania’s Philadelphia Court of Common ... proceeding with its bellwether trial program, as the ...
(Date:5/27/2015)... May 27, 2015 In today's healthcare ... tighter, it can be challenging for doctors and hospitals ... edge treatments. , Austin-based HealthTronics, Inc. ... invasive, mobile medical therapies for clinically sophisticated applications. The ... the acquisition of Laser Ventures, Inc ., a ...
Breaking Medicine News(10 mins):Health News:VA Begins “Summer of Service” to Bolster Volunteer Assistance for Veterans 2Health News:VA Begins “Summer of Service” to Bolster Volunteer Assistance for Veterans 3Health News:Blackhawks vs. Ducks NHL Western Conference Finals Tickets: Ticket Down Slashes Ticket Prices on Chicago Blackhawks vs. Anaheim Ducks 2015 NHL Western Conference Finals 2Health News:KVI announced the launch of The Keratoconus website focused on age based keratoconus treatment . 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 2Health News:Risperdal Lawsuit Attorneys at Bernstein Liebhard LLP Look Forward to Start of Third Gynecomastia Bellwether Trial in Pennsylvania 3Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 2Health News:HealthTronics Invests in Additional Mobile Medical Technologies As Cost Efficient Solution for Hospitals, Doctors 3
... announced today that the U.S. Food and Drug ... 360(TM) Orbital Atherectomy System (OAS),for removing plaque blockages ... device offers a promising new alternative for treating ... Disease,PAD. The clearance follows the successful completion ...
... BOSTON, Sept. 24 Small Army, the Boston-based ... for diabetes and,alleviating world poverty to their scope of ... "As communicators, we welcome the challenge to partner ... by a commitment,to truly make the world a better ...
... which advocates for physicians, joins forces with national, organization ... ... Americans, GREENSBORO, N.C., Sept. 24 Medical Justice,Services ... medical malpractice cases for the past five years, has,joined ...
... candidate from every Party to commit to creating a National ... ... Senator and,Presidential candidate John Edwards today released a policy paper calling,for ... for ensuring that every person living with HIV/AIDS,has access to quality ...
... who have had knee replacement surgery due to osteoarthritis ... on bmj.com today. , Osteoarthritis is the ... replacement surgery (knee arthroplasty) is a common procedure but ... out everyday tasks. , At present, it is ...
... Preparing Journalists to Cover the 2008 Health Care Proposals, WASHINGTON, Sept. ... Who: Journalists covering health care policy and the 2008 Presidential ... All-Expenses-Paid Four-Day Seminar for Journalists, A McCormick ... Available, When: November ...
Cached Medicine News:Health News:New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours 2Health News:New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours 3Health News:Small Army Takes on Cure for Diabetes and New Approach to Ending World Poverty with Addition of Non-Profit Accounts 2Health News:Medical Justice Services Inc. Joins Center for Health Transformation 2Health News:Medical Justice Services Inc. Joins Center for Health Transformation 3Health News:AIDS Action Council Commends Senator Edwards for Endorsing a National HIV/AIDS Strategy 2Health News:Health Care and the Presidential Campaign 2
Inquire...
... is ideal for repeated pipetting ... volume FInnpipettes offer the same ... Finnpipette Digital pipettes: New, ... Soft-touch tip ejection, Safety label, ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... The new Finnpipette Focus from ... to combine ergonomics with uncompromising ... handle plate offers a custom ... The new shorter tip cones ...
Medicine Products: